TaiMed Biologics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, TaiMed Biologics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 7 completed early-phase tilt top decile by trial count

TaiMed Biologics: 9 sponsored US clinical trials, 1 recruiting.

TaiMed Biologics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV-1-infection, with 1 trials.

Top-decile sponsor footprint

TaiMed Biologics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

NCT07215468
COMPLETED Phase 1

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

NCT05275998
COMPLETED Phase 1

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

NCT04027387
COMPLETED Phase 3

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

NCT03913195
TERMINATED Phase 1

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

NCT03110549
COMPLETED Phase 3

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

NCT02707861
COMPLETED Phase 3

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

NCT02475629
COMPLETED Phase 1

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers

NCT01292174
COMPLETED Phase 2

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

NCT00784147

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 3

Therapeutic Areas

HIV-1-infection 1

What is open in the TaiMed Biologics pipeline

1 recruiting of 9 indexed (11% open); 7 completed (78%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: HIV-1-infection (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

TaiMed Biologics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

TaiMed Biologics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share TaiMed Biologics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
TaiMed Biologics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

TaiMed Biologics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this TaiMed Biologics page

9 registered trials is a research-attention snapshot, not an endorsement of TaiMed Biologics or any single study.

  • 1 of TaiMed Biologics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • HIV-1-infection is the condition TaiMed Biologics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV-1-infection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

TaiMed Biologics pipeline card: 9 registered trials from official public datasets.Report a data error.